Abstract
Drug development companies in APAC need to raise their game to capitalise on the $33bn+ immuno-oncology treatment opportunity Singapore’s pharmaceutical market value to reach $1.15 billion by 2021 Ryzodeg reduces hypoglycaemia in type 2 diabetic fasting patients FDA approves Amgen’s Repatha (evolocumab) to prevent heart attack and stroke FDA approves first drug for rare disease, eosinophilic granulomatosis with polyangiitis FDA approves first biosimilar for the treatment of certain breast and stomach cancers FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss Singapore institutes collaborate with Samsung Medical Center to improve treatment of liver cancer Globavir announces partnership with Singhealth Duke-NUS Academic Medical Centre to study dengue treatment Mundipharma secures exclusive license for the development and commercialisation of PAION’s remimazolam in Japan
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
